Core Viewpoint - The mRNA drug developer DeepTrust Bio plans to go public in Hong Kong, potentially raising around $200 million, with discussions on IPO scale and timing still in preliminary stages [1] Company Overview - DeepTrust Bio was established in 2019 and is one of the few companies globally that possesses core technology for LNP (lipid nanoparticle) design [1] - The company has developed an mRNA-LNP technology platform with proprietary intellectual property, including a library of over 5,000 ionizable lipid resources for screening LNP carriers suitable for various therapeutic scenarios [1] - DeepTrust Bio has multiple internal research pipelines in the fields of infectious disease vaccines, rare diseases, and tumor immunotherapy [1] Investment Background - According to Qichacha data, DeepTrust Bio has undergone several rounds of financing, with investors including Huaxing Capital, Dinghui Investment, CPE Yuanfeng, Qianhai Fangyuan Capital, E Fund, Blue Ocean Capital, Zhongke Chuangxing, Qianhai Mother Fund, Dongpingheng Capital, Junlian Capital, Zhifei Biological, and Lanting Capital [1]
新股消息 | 传mRNA药企深信生物拟赴港上市 或募资约2亿美元
智通财经网·2025-10-22 07:21